ALS Drug Needs More Evidence, FDA Advisors Say
In a close call, an FDA advisory committee said data from a single trial for AMX0035, an investigational agent being studied to treat amyotrophic lateral sclerosis (ALS), did not support a conclusion that the drug was effective. The 6-4 vote of the Peripheral and Central Nervous System Drugs Advisory Committee was based on findings from […]